Nasar Chaudhry
Internal Medicine · Hornell, NYNPI 1225037203
Payments from drug & device makers
Across 93 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$373
- Astellas Pharma US Inc$208
- AbbVie$193
- Novo Nordisk$142
- Johnson & Johnson$138
- Kowa Pharmaceuticals America, Inc.$132
- plus $406 from 12 others
What the payments were for
- Food & beverage$1,35285%
- Education$24115%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $373 |
| Astellas Pharma US Inc | 6 | $208 |
| AbbVie | 9 | $193 |
| Novo Nordisk | 11 | $142 |
| Johnson & Johnson | 10 | $138 |
| Kowa Pharmaceuticals America, Inc. | 9 | $132 |
| Amgen | 4 | $73 |
| Sunovion Pharmaceuticals Inc. | 3 | $55 |
| GSK | 4 | $50 |
| Boehringer Ingelheim | 3 | $47 |
| Irhythm Technologies, Inc. | 1 | $34 |
| Lilly USA, LLC | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 1 | $25 |
| Pfizer | 2 | $25 |
| Merck | 1 | $22 |
| Bayer | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$1,593 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 35 | $50,095 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $45,331 |
| RybelsusSemaglutide | 18 | $45,036 |
| FarxigaDapagliflozin Propanediol | 37 | $42,534 |
| EliquisApixaban | 37 | $37,402 |
| XareltoRivaroxaban | 23 | $34,625 |
| TrulicityDulaglutide | 14 | $20,935 |
| GlyxambiEmpagliflozin/Linagliptin | 18 | $19,768 |
| MyrbetriqMirabegron | 13 | $15,573 |
| VascepaIcosapent Ethyl | 13 | $10,112 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $4,673 |
| Novolog FlexpenInsulin Aspart | 13 | $4,043 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $2,832 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $2,044 |
| Rosuvastatin Calcium | 111 | $1,893 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi | $47 | $69,86353 claims |
| GSKTrelegy Ellipta | $50 | $45,33133 claims |
| Novo NordiskRybelsus | $142 | $45,03618 claims |
| AstraZenecaFarxiga | $373 | $42,53437 claims |
| PfizerEliquis | $25 | $37,40237 claims |
| Johnson & JohnsonXarelto | $138 | $34,62523 claims |
| Lilly USA, LLCTrulicity | $29 | $20,93514 claims |
| Astellas Pharma US IncMyrbetriq | $208 | $15,57313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Hornell
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.